Beta Bionics
Developer of an automated insulin delivery system (iLet Bionic Pancreas) and associated software and services. Offers closed‑loop insulin dosing algorithms that integrate with continuous glucose monitoring (CGM) sensors, mobile and remote‑monitoring applications, patient training, and payer/pharmacy workflows. Describes clinical research and real‑world data collection supporting the system. Founded in 2015 with locations in California and Massachusetts.
Industries
Nr. of Employees
large (251-1000)
Beta Bionics
Patents
Products
iLet Bionic Pancreas (automated insulin delivery device)
A wearable automated insulin delivery device that uses CGM data and embedded algorithms to determine 100% of insulin dosing; supports meal announcements (qualitative carb estimates), correction and basal adjustments, and connection to mobile apps and remote monitoring.
Bionic Circle (remote monitoring app)
Mobile app functionality that allows selected caregivers to view CGM values, meal announcements, insulin doses and receive defined alerts.
iLet
An infusion set featuring a 90-degree soft cannula delivered ready to use in a pre-loaded insertion device with automatic needle retraction for subcutaneous infusion of insulin in the treatment of diabetes mellitus.
iLet Bionic Pancreas
An automated insulin delivery system that determines 100% of insulin doses using fully autonomous meal, basal, and correction algorithms that continuously learn and adapt to the individual.
iLet ACE Pump
An alternate controller enabled pump intended to deliver insulin under the skin based on input from an integrated continuous glucose monitor and an interoperable automated glycemic controller.
iLet Dosing Decision Software
Software intended for use with compatible integrated continuous glucose monitors and alternate controller enabled pumps to autonomously determine and command insulin doses.
iLet Bionic Pancreas (automated insulin delivery device)
A wearable automated insulin delivery device that uses CGM data and embedded algorithms to determine 100% of insulin dosing; supports meal announcements (qualitative carb estimates), correction and basal adjustments, and connection to mobile apps and remote monitoring.
Bionic Circle (remote monitoring app)
Mobile app functionality that allows selected caregivers to view CGM values, meal announcements, insulin doses and receive defined alerts.
iLet
An infusion set featuring a 90-degree soft cannula delivered ready to use in a pre-loaded insertion device with automatic needle retraction for subcutaneous infusion of insulin in the treatment of diabetes mellitus.
iLet Bionic Pancreas
An automated insulin delivery system that determines 100% of insulin doses using fully autonomous meal, basal, and correction algorithms that continuously learn and adapt to the individual.
iLet ACE Pump
An alternate controller enabled pump intended to deliver insulin under the skin based on input from an integrated continuous glucose monitor and an interoperable automated glycemic controller.
iLet Dosing Decision Software
Software intended for use with compatible integrated continuous glucose monitors and alternate controller enabled pumps to autonomously determine and command insulin doses.
Services
Payer/pharmacy program that verifies pharmacy benefit eligibility, provides a free initial period for eligible commercially insured patients, and coordinates device and supply shipment; concierge handling for DME customers.
Training delivered by certified device trainers to onboard new users and ensure safe device operation.
Around‑the‑clock technical support for device operation and app connectivity, plus sales support for prescription and insurance questions.
Payer/pharmacy program that verifies pharmacy benefit eligibility, provides a free initial period for eligible commercially insured patients, and coordinates device and supply shipment; concierge handling for DME customers.
Training delivered by certified device trainers to onboard new users and ensure safe device operation.
Around‑the‑clock technical support for device operation and app connectivity, plus sales support for prescription and insurance questions.
Expertise Areas
- Automated insulin delivery systems
- Closed‑loop control algorithm development
- Continuous glucose monitoring integration
- Clinical training and patient onboarding
Key Technologies
- Automated/closed‑loop insulin delivery (AID)
- Continuous glucose monitoring (CGM) integration
- Embedded insulin dosing control algorithms
- Mobile health applications
News & Updates
Citation of a 2023 peer‑reviewed article reporting psychosocial outcomes for users and caregivers associated with the insulin‑only automated insulin delivery system.
States over 12 years of clinical research and completion of 20 pre‑pivotal trials supporting product development.
Company founded on October 21, 2015.
Citation of a 2023 peer‑reviewed article reporting psychosocial outcomes for users and caregivers associated with the insulin‑only automated insulin delivery system.
States over 12 years of clinical research and completion of 20 pre‑pivotal trials supporting product development.
Company founded on October 21, 2015.